NCT07566286 Study to Evaluate the Safety of Retreatment With Restylane® Lyft With Lidocaine for Augmentation of the Chin Region
| NCT ID | NCT07566286 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Galderma R&D |
| Condition | Chin Augmentation |
| Study Type | INTERVENTIONAL |
| Enrollment | 100 participants |
| Start Date | 2026-06-03 |
| Primary Completion | 2027-11-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 100 participants in total. It began in 2026-06-03 with a primary completion date of 2027-11-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The primary objective of this study is to evaluate the safety of Restylane Lyft with Lidocaine for augmentation of the chin region 3 months after retreatment.
Eligibility Criteria
Inclusion Criteria: 1. Males or non-pregnant, non-breastfeeding females, 22 years of age or older. 2. Intent to receive treatment for augmentation and correction of retrusion in the chin region. Exclusion Criteria: 1. Known/previous allergy or hypersensitivity to any injectable hyaluronic acid (HA) gel or to gram positive bacterial proteins. 2. Known/previous allergy or hypersensitivity to local anesthetics, e.g. lidocaine or other amide-type anesthetics. 3. Previous or present multiple allergies or severe allergies, such as manifested by anaphylaxis or angioedema, or family history of these conditions. 4. Previous facial surgery (including facial aesthetic surgery and liposuction), below the level of the horizontal line from subnasale. 5. Any previous aesthetic procedures or implants. 6. Presence of any disease or lesions near or on the area to be treated.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07566286 clinical trial?
This trial is open to participants of all sexes, aged 22 Years or older, studying Chin Augmentation. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07566286 currently recruiting?
Yes, NCT07566286 is actively recruiting participants. Contact the research team at clinical.studies@galderma.com for enrollment information.
Where is the NCT07566286 trial being conducted?
This trial is being conducted at Westport, United States, Boynton Beach, United States, Coral Gables, United States, Coral Gables, United States and 4 additional locations.
Who is sponsoring the NCT07566286 clinical trial?
NCT07566286 is sponsored by Galderma R&D. The trial plans to enroll 100 participants.